Designed ATRA analogue active against ATRA-resistant acute promyelocytic leukemia cells having a single nucleotide substitution in their retinoic acid receptor

Leukemia Research

Volumn 31, Issue 3, 2007, Pages 301-313

  Komura, Naoyuki ^a   Ikeda, Yoko ^b   Masuda, Natsuko ^a   Umezawa, Yoji ^b   Ito, Keisuke ^a   Kizaki, Masahiro ^a   Umezawa, Kazuo ^a  

^a KEIO UNIVERSITY   (Japan)

^b Microbial Chemistry Research Foundation   (Japan)

Author keywords

Acute promyelocytic leukemia (APL); All trans retinoic acid (ATRA); Apoptosis; ATRA resistance; Differentiation; Et ketone ATRA; Molecular design

Indexed keywords

5,9 DIMETHYL 11 (2,6,6 TRIMETHYLCYCLOHEX 1 ENYL)UNDECA 4,6,8,10 TETRAEN 3 ONE; BIOLOGICAL MARKER; CARBOXYLIC ACID DERIVATIVE; CD11B ANTIGEN; KETONE DERIVATIVE; PROTEIN BAX; PROTEIN P21; REACTIVE OXYGEN METABOLITE; RETINOIC ACID; RETINOIC ACID DERIVATIVE; RETINOIC ACID RECEPTOR; RETINOIC ACID RECEPTOR ALPHA; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL DIFFERENTIATION; CONTROLLED STUDY; DRUG STRUCTURE; DRUG TARGETING; HUMAN; HUMAN CELL; HYDROPHOBICITY; LEUKEMIA CELL; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; SINGLE NUCLEOTIDE POLYMORPHISM; UPREGULATION;

ANTIGENS, CD11B; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CELL DIFFERENTIATION; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; GENE THERAPY; HL-60 CELLS; HUMANS; HYDROPHOBICITY; LEUKEMIA, PROMYELOCYTIC, ACUTE; MOLECULAR STRUCTURE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; POINT MUTATION; REACTIVE OXYGEN SPECIES; RECEPTORS, RETINOIC ACID; STRUCTURE-ACTIVITY RELATIONSHIP; TRETINOIN;

EID: 33846039899     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2006.07.015     Document Type: Article

References (37)

1. Breitman T., Collins S.J., and Keene B. Terminal differentiation of human promeylocytic cells in culture in response to retinoic acid. Blood 57 (1981) 1000-1004
2. Rowley J., Golumb H., and Dougherty C. 15/17 translocation a consistent chromosomal change in acute promyelocytic leukemia. Lancet 1 (1977) 549-550
3. de The H., Chomienne C., Lanotte M., Degos L., and Dejean A. The t(15; 17) translocation of acute promyelocytic leukaemia fuses the retinoic acid receptor alpha gene to a novel transcribed locus. Nature 347 (1990) 558-561
4. Largman C., Detmer K., Corral J.C., Hack F.M., and Lawrence H.J. Expression of retinoic acid receptor alpha mRNA in human leukemia cells. Blood 74 (1989) 99-102
5. Liu T.X., Zhang J.W., Tao J., Zhang R.B., Zhang Q.H., Zhao C.J., et al. Gene expression networks underlying retinoic acid-induced differentiation of acute promyelocytic leukemia cells. Blood 96 (2000) 1496-1504
6. Jiang H., Lin J., Su Z.Z., Collart F.R., Huberman E., and Fisher P.B. Induction of differentiation in human promyelocytic HL-60 leukemia cells activates p21, WAF1/CIP1, expression in the absence of p53. Oncogene 9 (1994) 3397-3406
7. Whyte P., and Eisenman R.N. Dephosphorylation of the retinoblastoma protein during differentiation of HL60 cells. Biochem Cell Biol 70 (1992) 1380-1384
8. Borden K.L., CampbellDwyer E.J., and Salvato M.S. The promyelocytic leukemia protein PML has a pro-apoptotic activity mediated through its RING domain. FEBS Lett 418 (1997) 30-34
9. Yoshida H., Kitamura K., Tanaka K., Omura S., Miyazaki T., Hachiya T., et al. Accelerated degradation of PML-retinoic acid receptor alpha oncoprotein by all-trans retinoic acid in acute promyelocytic leukemia: possible role of the proteasome pathway. Cancer Res 56 (1996) 2945-2948
10. Duprez E., Saurin A.J., Desterro J.M., Lallemand-Breitenbach V., Howe K., Boddy M.N., et al. SUMO-1 modification of the acute promyelocytic leukaemia protein PML: implications for nuclear localisation. J Cell Sci 112 (1999) 381-393
11. Pearson M., Carbone R., Sebastiani C., Cioce M., Fagioli M., Saito S., et al. PML regulates p53 acetylation and premature senescence induced by oncogenic Ras. Nature 406 (2000) 207-210
12. Borden K.L. Pondering the promyelocytic leukemia protein (PML) puzzle: possible functions for PML nuclear bodies. Mol Cell Biol 22 (2002) 5259-5269
13. Imaizumi M., Suzuki H., Yoshinari M., Sato A., Saito T., Sugawara A., et al. Mutations in the E-domain of RAR portion of the PML/RAR chimeric gene may confer clinical resistance to all-trans retinoic acid in acute promyelocytic leukemia. Blood 92 (1998) 374-382
14. Slack J.L., Willman C.L., Andersen J.W., Li Y.P., Viswanatha D.S., Bloomfield C.D., et al. Molecular analysis and clinical outcome of adult APL patients with the type V PML-RARalpha isoform: results from intergroup protocol 0129. Blood 95 (2000) 398-403
15. Ding W., Li Y.P., Nobile L.M., Grills Q., Carrera I., Paietta E., et al. Leukemic cellular retinoic acid resistance and missense mutations in the PML-RARalpha fusion gene after relapse of acute promyelocytic leukemia from treatment with all-trans retinoic acid and intensive chemotherapy. Blood 92 (1998) 172-183
16. Zhou D.C., Kim S.H., Ding W., Schultz C., Warrell Jr. R.P., and Gallagher R.E. Frequent mutations in the ligand-binding domain of PML-RARalpha after multiple relapses of acute promyelocytic leukemia: analysis for functional relationship to response to all-trans retinoic acid and histone deacetylase inhibitors in vitro and in vivo. Blood 99 (2002) 1356-1363
17. Kizaki M., Matsushita H., Takayama N., Muto A., Ueno H., Awaya N., et al. Establishment and characterization of a novel acute promyelocytic leukemia cell line (UF-1) with retinoic acid-resistant features. Blood 88 (1996) 1824-1833
18. Takayama N., Kizaki M., Hida T., Kinjo K., and Ikeda Y. Novel mutation in the PML/RARalpha chimeric gene exhibits dramatically decreased ligand-binding activity and confers acquired resistance to retinoic acid in acute promyelocytic leukemia. Exp Hematol 29 (2001) 864-872
19. Marasca R., Zucchini P., Galimberti S., Leonardi Q., Vaccari P., Donelli A., et al. Mutations in the PML/RARalpha ligand binding domain in ATRA-resistant As(2)O(3) sensitive relapsed acute promyelocytic leukemia. Haematologica 84 (1999) 963-968
20. Shao W., Benedetti L., Lamph W.W., Nervi C., and Miller Jr. W.H. A retinoid-resistant acute promyelocytic leukemia subclone expresses a dominant negative PML-RAR alpha mutation. Blood 89 (1997) 4282-4289
21. Zhang Z.P., Gambone C.J., Gabriel J.L., Wolfgang C.L., Soprano K.J., and Soprano D.R. Arg278, but not Lys229 or Lys236, plays an important role in the binding of retinoic acid by retinoic acid receptor gamma. J Biol Chem 273 (1998) 34016-34021
22. Renaud J.P., Rochel N., Ruff M., Vivat V., Chambon P., Gronemeyer H., et al. Crystal structure of the RAR-gamma ligand-binding domain bound to all-trans retinoic acid. Nature 378 (1995) 681-689
23. Nahm S., and Weinreb S.M. N-Methoxy-n-methylamides as effective acylating agents. Tetrahedron Lett 22 (1981) 3815-3818
24. Gianni M., Ponzanelli I., Mologni L., Reichert U., Rambaldi A., Terao M., et al. Retinoid-dependent growth inhibition, differentiation and apoptosis in acute promyelocytic leukemia cells. Expression and activation of caspases. Cell Death Differ 7 (2000) 447-460
25. Breitman T., Collins S.J., and Keene B. Terminal differentiation of human promeylocytic cells in culture in response to retinoic acid. Blood 57 (1981) 1000-1004
26. Chen Q., and Catharine Ross A. Retinoic acid regulates cell cycle progression and cell differentiation in human monocytic THP-1 cells. Exp Cell Res 297 (2004) 68-81
27. Yamaguchi T., Maeda Y., Ueda S., Hijikata Y., Morita Y., Miyatake J.I., et al. Dichotomy of all-trans retinoic acid inducing signals for adult T-cell leukemia. Leukemia 19 (2005) 1010-1017
28. Bhatia M., Kirkland J.B., and Meckling-Gill K.A. 25-Dihydroxyvitamin D3 primes acute promyelocytic cells for TPA-induced monocytic differentiation through both PKC and tyrosine phosphorylation cascades. Exp Cell Res 222 (1996) 61-69
29. Bhatia M., Kirkland J.B., and Meckling-Gill K.A. Monocytic differentiation of acute promyelocytic leukemia cells in response to 1,25-dihydroxyvitamin D3 is independent of nuclear receptor binding. J Biol Chem 270 (1995) 15962-15965
30. Hickstein D.D., Baker D.M., Gollahon K.A., and Back A.L. Identification of the promoter of the myelomonocytic leukocyte integrin CD11b. Proc Natl Acad Sci USA 89 (1992) 2105-2109
31. Liu M., Iavarone A., and Freedman L.P. Transcriptional activation of the human p21(WAF1/CIP1) gene by retinoic acid receptor. Correlation with retinoid induction of U937 cell differentiation. J Biol Chem 271 (1996) 31723-31728
32. Doyle B.T., O'Neill A.J., Fitzpatrick J.M., and Watson R.W. Differentiation-induced HL-60 cell apoptosis: a mechanism independent of mitochondrial disruption?. Apoptosis 9 (2004) 345-352
33. 3) in the treatment of acute promyelocytic leukemia (APL): clinical efficacy and pharmacokinetics in relapsed patients. Blood 89 (1997) 3354-3360
34. Soignet S.L., Frankel S.R., Douer D., Tallman M.S., Kantarjian H., Calleja E., et al. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol 19 (2001) 3852-3860
35. Tallman M.S., Nabhan C., Feusner J.H., and Rowe J.M. Acute promyelocytic leukemia: evolving therapeutic strategies. Blood 99 (2002) 759-767
36. Heyman R.A., Mangelsdorf D.J., Dyck J.A., Stein R.B., Eichele Q., Evans R.M., et al. 9-Cis retinoic acid is a high affinity ligand for the retinoid X receptor. Cell 68 (1992) 397-406
37. Dawson M.I., Elstner E., Kizaki M., Chen D.L., Pakkala S., Kerner B., et al. Myeloid differentiation mediated through retinoic acid receptor/retinoic X receptor (RXR) not RXR/RXR pathway. Blood 84 (1994) 446-452